Monthly Reports
Data sets are refreshed often, sometimes daily. Refreshed insights are reported monthly to support decision-making with the best available information and intelligence.
Supply Chain Mapping
USP enhances US FDA public data with international, trade and USP proprietary data. Labeler, finished drug product (FDP) manufacturer, and active pharmaceutical ingredient (API) manufacturer facilities are linked to the 9-digit National Drug Codes (NDCs) to provide end-to-end supply chain visibility.
Drug Shortage Predictions
USP's drug resiliency model leverages neural networks to analyze hundreds of drug/ facility/ organization characteristics to predict the likelihood that a drug may be in shortage in 4-6 months and 7-12 months, giving stakeholders time to prepare for shortages.
Quantified Drug Shortage Drivers
The healthcare industry specializes in diagnosis before treatment, and it should be no different for drug shortages. Risk contributors, like historic shortages, site inspections and market economics, are delineated within Medicine Supply Map so users can understand what is driving risk in a product and take targeted mitigation actions.
Market Share Data
Drugs with high shortage vulnerability and large market share pose the greatest shortage risk. With integrated market share data, the model prioritizes drugs where shortages will have the highest impact.
Inspection Results, Warning Letters, and Recalls
The monthly Medicine Supply Map reports include the latest FDA inspection results, warning letters, and manufacturer recalls – all of importance when evaluating drug shortage warning signals.
Dashboard
The report dashboard visualizes trends in drug supply resiliency, giving insight into the overall number of shortages and high-risk drugs as shortage pressures increase or decrease.
Model Performance Transparency
Model performance results are published monthly, including accuracy, false positive and false negative rates
Increase supply chain visibility
Quickly understand the drug manufacturing landscape and know what drugs may be impacted by supply shock events. The tool maps 91% of finished drug product and over 44% of Active Pharmaceutical Ingredient (API) manufacturers to National Drug Code (NDC) groups for drugs sold in the U.S.
Plan for drug shortage impacts
Vulnerability scores can predict the likelihood of a drug product being in shortage 12 months in advance. When combined with proprietary market share data, users can identify high-risk and high-impact drug products that may be at risk of shortage long before the potential shortage occurs, giving time to secure raw materials and reserve equipment to meet the demands of supply disruptions.
Promote availability of quality medicines for patients and customers
There were over 300 active drug shortages in the U.S. in 2023 – the highest rates seen in decades – representing millions of affected patients and significant lost sales. Supply chain and risk insights from the Medicine Supply Map can help to ensure that medicine demand is met, reducing the frequency and duration of drug shortages.
Providing supply chain intelligence to:
Government
Inform policy and funding decisions to help prevent or mitigate drug shortages, improve medicine supply chain resiliency, and strengthen national security.
Health Systems and Hospitals
Get more time to plan by gaining early visibility into medicines affected by supply disruptions.
Manufacturers and CDMOs
Make more informed planning and production decisions by understanding how drug shortage risks lead to unmet medicine demand.
Distributors
Control drug shortage costs while helping to ensure available medicines supply with continuity plans informed by medicines supply chain intelligence.
Insights on supply chain vulnerability
Read original analysis about the global distribution of APIs and risks associated with specific drug classes, from broadly used medicines to those that are critically needed in small populations.
Learn more
